GlassScriptPhysician profile
Douglas Jordan Grunwald
NPI 1154616001
$4,815.45
in general payments reported to CMS, 2019-2025
32 companies · $1,657 in 2025
The $1,657 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $618 · 2020: $118 · 2021: $197 · 2022: $245 · 2023: $757 · 2024: $1,223 · 2025: $1,657.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,607 · Education: $30.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,606.59 |
| Education | $30.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,080.25 | 2019-2025 | |
| Ardelyx, INC. | $464.76 | 2023-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $435.48 | 2019-2025 | Entyvio |
| Qol Medical, LLC | $295.62 | 2024-2025 | Sucraid, Sucraid |
| Madrigal Pharmaceuticals | $289.87 | 2025 | Rezdiffra |
| Gilead Sciences, INC. | $271.98 | 2019-2025 | |
| Pfizer INC. | $240.26 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $221.29 | 2019-2025 | Xifaxan, Trulance |
| Genzyme Corporation | $159.77 | 2023-2025 | |
| Lilly USA, LLC | $158.29 | 2024-2025 | Omvoh |
| Pentax of America, INC. | $153.78 | 2021-2022 | |
| Janssen Biotech, INC. | $144.23 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Celgene Corporation | $139.77 | 2023-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $104.39 | 2020-2025 | Ocaliva |
| Medtronic, INC. | $69.09 | 2025 | Barrx |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $67.59 | 2019-2024 | Rebyota |
| Phathom Pharmaceuticals, INC. | $67.34 | 2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $53.88 | 2024-2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $48.02 | 2024 | |
| Evoke Pharma, INC. | $44.52 | 2023-2025 | Gimoti |
| Organon LLC | $33.94 | 2023 | Hadlima |
| Endo Pharmaceuticals INC. | $33.38 | 2019 | |
| Shionogi INC | $31.45 | 2019 | |
| Allergan, INC. | $29.08 | 2019 | |
| Aimmune Therapeutics, INC. | $28.21 | 2024 | |
| Exact Sciences Corporation | $27.14 | 2024 | Cologuard Collection Kit |
| Fresenius Kabi USA, LLC | $25.71 | 2023 | Idacio |
| Laborie Medical Technologies Corp. | $25.23 | 2025 | Alphaone |
| Braintree Laboratories, INC. | $20.00 | 2023 | Sutab |
| Daiichi Sankyo INC. | $19.50 | 2019 | |
| Portola Pharmaceuticals, LLC | $18.47 | 2020 | |
| Coloplast Corp | $13.16 | 2023 | Peristeen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Grunwald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.